Therapeutic preparations of IVIg have high levels of HLA (Ia & Ib) reactivity.
INTRODUCTION
1/2, 1/4 and 1/8 dilutions to test against regular beads (lot #7) and iBeads (Lot # 6). HLA-Ia alleles on regular beads may occur both as intact HLA with β2microglobulin (β2m) as well as heavy chains without β2m. The manufacturer of HLA beads (One Lambda, Inc) has recently generated beads with reduced amounts of β2m-free HLA, called iBeads. Differences in the reactivity of IVIg preparations to regular beads and iBeads may indicate whether IVIg binds more to intact HLA or to HLA heavy chain. All mAbs were also tested on iBeads. In addition, we used purified human IgG from Southern Biotech, (cat. No: 0150-01, Birmingham, AL, USA).
Sources of normal human sera
Sera from non-alloimmunized males, frozen and stored at the Terasaki Foundation Laboratory (TFL), were used. Informed consent was obtained by Dr. Morales-Buenrostro from the healthy volunteers in Mexico, by Dr. Ali Hajeer (King Fahad NG Hospital), from those in Ryadh, Kingdom of Saudi Arabia. IgG from some of the sera of normal non-alloimmunized males was purified using protein-G column as described earlier 19 .
Immunoassay with single-HLA-antigen-coated microbeads
To detect IgG reactivity to HLA-E and HLA-Ia alleles in IVIg/purified human IgG/ murine mAbs, multiplex Luminex ® -based immunoassay (One Lambda, Inc., Canoga Park, CA) was used, as described elsewhere [13] [14] [15] . IVIg and standard human IgG from commercial sources were serially diluted (from 1/2 , ending in 1/256) with phosphate-buffered saline (PBS, pH 7.2) and added to the wells containing the antigen-coated microbeads. Anti-HLA-E mAbs were developed in-house (vide infra), and the supernatants collected from the hybridoma culture were used without dilution. Using dual-laser flow cytometry (Luminex xMAP ® multiplex technology), the single antigen assays were carried out for data acquisition and analysis of anti-HLA-Ia and anti-HLA-E Abs [13] [14] [15] . The LABScreen ® Single Antigen (One Lambda) assay consists of a panel of color-coded microspheres (single antigen beads), coated with HLA antigens to identify antibody specificities. The single recombinant HLA-Ia antigens in LS1A04-Lot 003, 004 and 005 were used for screening IVIg and human standard IgG. This lot contains 31 HLA-A, 50 HLA-B and 16 HLA-Cw allelic molecules. The beads supplied by the manufacturer may have two categories of proteins attached to the beads: HLA heavy-chain polypeptide only and heavy-chain polypeptides in association with β2microglobulin. Realizing For personal use only. on October 28, 2017. by guest www.bloodjournal.org From the heterogeneity of proteins, the manufacturer has recently developed iBeads ( provided to us as Felix beads for in-house experimental use), which are regular HLA-Ia antigen-coated microbeads subjected to proprietary enzymatic treatment to remove or reduce the amount of heavy chains (also referred to as "denatured antigens") by the manufacturers. The recombinant HLA-E, HLA-F and HLA-G folded heavy chains (10 mg/ml in MES buffer) were obtained from the Immune Monitoring Lab, Fred Hutchinson Cancer Research Center (University of Washington, Seattle, WA). The recombinant HLA-E, HLA-F and HLA-G heavy chains are individually attached by a process of simple chemical coupling to 5.6 μm polystyrene microspheres, which are internally dyed by One Lambda with infrared fluorophores [13] [14] [15] . The HLA-Ia microbeads have built-in control beads: positive beads, coated with human IgG (or murine IgG, when mAb was used) and negative beads, coated with serum albumin (HSA/BSA). For HLA-E, HLA-F and HLA-G, the control beads (both positive and negative) were added separately. Data generated with Luminex Multiplex Flow Cytometry (LABScan 100) were analyzed using the same computer software and protocols as reported earlier [13] [14] [15] . For each analysis, at least 100 beads were counted. Mean and standard deviation of MFI for each allele were recorded. All the data were stored and archived at TFL; basic statistical analyses were made with Excel software.
Affinity Chromatography
To determine whether the HLA-Ia reactivity of IVIg is due to the presence of HLA-E antibodies in IVIg, the recombinant HLA-E heavy-chain polypeptide (6 mg) was dialyzed overnight at 4 o C against a sodium bicarbonate buffer (0.1M NaHCO 3 , pH 8.5) to remove urea and DTT. For conjugating HLA-E to Affi-Gel 10, Affi-Gel 10 was washed with distilled water and sodium bicarbonate buffer for 20 minutes. After removing supernatant, HLA-E (6 mg) in 1 ml of buffer was mixed with 338 μ l of the Affi-Gel 10 suspension. The mixture was kept in a refrigerator overnight on an inverting rotator. The tube was taken out and centrifuged at 600g for five minutes. The supernatant was recovered and the gel washed three times in distilled water and twice with a carbonate buffer. After removing the supernatant completely, 100 μl of IVIg
(1/128 dilution) was added to the gel and mixed well. The HLA-E/Affi-Gel 10/ IVIg
(1/128dilution) mixture was placed on an inverter for one hour. Meanwhile, 100 μl of 1/128diluted IVIg was further serially diluted (1/128, 1/256, 1/512 and 1/1024, to a total volume of 50 μl). IVIg adsorbed to HLA-E gel (or control Affi-Gel 10 without HLA-E) was recovered and designated eluate 1a and 1b. Eluate 1 was also serially diluted, as above. The entire sets were tested against HLA-E beads and HLA-Ia beads. IVIg used for this specific experiment came from the same batch as the original, but had been stored in aliquots in the refrigerator for six months. Consequently, the IVIg used in the experiment had reduced potency in binding to HLA, but did bind 1/4 of the original. The MFI of anti-HLA-E reactivity was >18,000-but only 4,500
for the stored aliquots.
Production of murine monoclonal antibodies against HLA-E R107 and HLA-E G107
Essentially, these antibodies were produced following the guidelines in the report 
Results
Normal male and female sera showed both HLA class-Ia and -Ib reactivity.
Sera of normal non-alloimmunized males and healthy females were examined for Abs reacting to HLA-E and HLA class-Ia (HLA-A, HLA-B and HLA-Cw) alleles 13[Fig.3] . We have noted that 66% of the sera with HLA-E IgG showed intense reactivity to several HLA-Ia alleles.
The same sera of non-alloimmunized males that showed reactivity to HLA-E and HLA-Ia alleles also showed reactivity to all of the HLA-Ib alleles (HLA-E, HLA-F & HLA-G) (Fig. 1) . The difference in MFI of anti-HLA-E Abs could be due to differences in the microbeads or due to differences in the density of recombinant HLA-E used to conjugate onto the beads. Notably, the sera with HLA-E Abs and HLA-Ia reactivity also reacted with HLA-F and HLA-G. Such reactivity could be due either to individual Abs reacting with these alleles (HLA-Ia or -Ib) or to the possibility that anti-HLA-E IgG per se may react with all other HLA-I alleles.
IgG purified from sera of normal males-negative for HLA-E or HLA-Ia alleles-showed anti-HLA-E reactivity concomitant with HLA-Ia reactivity.
Earlier 13 , we noted that 70% of sera that did not contain HLA-E Abs showed no reactivity to HLA-Ia alleles. To verify whether the presence of HLA-E Abs is revealed after purifying the sera, sera of five normal, healthy non-alloimmunized volunteers in Saudi Arabia were purified using protein-G columns. Three eluates were collected from each serum. The five sera were examined for Abs reacting to HLA-E, HLA-F and HLA-G. Figure 2A shows that all three eluates of all five sera, which had very few or no anti-HLA-E Abs, showed the presence of anti-HLA-E IgG. Figure 2B shows that all three eluates of the four out of five sera that had no reactivity to HLA-Ia alleles not only contained anti-HLA-E IgGs but also possessed HLA-Ia reactivity. The sera per se had highly restricted (AB44489) or no reactivity (AB44486, AB44488, AB44506) to HLA-Ia alleles. The IgG purified from two of the four sera (AB44486, AA44488) showed Cw-allele-restricted reactivity. These observations document that even those sera showing no detectable anti-HLA-E Abs or HLA-Ia reactivity contained both anti-HLA-E IgG and HLA-Ia reactivity upon purification. The alleles of HLA-Ia exhibiting reactivity to protein-G purified human sera are strikingly similar, in that reactivity, to the high incidence HLA-Ia reactivity observed in normal human sera and anti-HLA-E mAb MEM-E/02 14[ Table 5 ] .
This suggests that anti-HLA-E IgG in the protein-G purified normal human sera may mimic HLA-Ia reactivity.
Purified human IgG reactive to HLA-E also showed HLA-Ia reactivity.
Purified human IgG is available commercially, and is a standard for immunoassays.
Often, these commercial preparations are made from sera of four or five normal and healthy volunteers. One such preparation, obtained from Southern Biochem, was examined to verify whether it contained both anti-HLA-E Abs and anti-HLA-Ia reactivity as in protein-G purified human sera. Figure 3 shows that the IgG purified from the sera of normal non-alloimmunized males reacts to HLA-Ia alleles (to avoid alloimmunized individuals, female sera were not used).
We have earlier 13 reported that anti-HLA-I Abs in females react to HLA-E, HLA-F and HLA-G at different dilutions, with higher affinity for HLA-E. Table 1 shows Table 5 ] .
Anti-HLA-Ia and Anti-HLA-Ib of IVIg.
All four IVIg preparations showed a wide variety of reactivity to classical HLA-Ia (HLA-A, HLA-B and HLA-Cw) coated on microbeads. The four IVIg preparations were serially diluted from 2 to 1024 with PBS and tested against single-antigen-coated microbeads containing 31 allelic proteins of HLA-A, 50 proteins of HLA-B alleles and 16 proteins of HLA-C. The MFI values obtained for different HLA alleles at each dilution of IVIg were corrected against the corresponding MFI obtained with albumin-coated negative control beads. Table 3 shows that all the IVIg preparations reacted with several alleles of HLA-A, HLA-B and HLA-Cw. GamaStan recognized the highest number of alleles in each category. Figure 5 illustrates dosimetric variations in the HLA-Ia allelic recognition of the three different preparations of IVIg.
Essentially, all IVIg preparations showed stronger reactivity to Cw alleles, followed by B and then A alleles. IVIg reacted with all 16 Cw alleles tested. Comparing the preparations shown in Figure 5 , it may be noted that the highest reactivity was observed with Cw*0102, Cw*0501, Cw*0602, Cw*0801, Cw*1502, Cw*1601, Cw*1601 and Cw1802. The Cw* reactivity of IVIg is comparable to the high incidence of HLA-Ia reactivities found in normal sera 11 . IVIg reacted with several B* alleles, high reactivity observed with B*8201, B*1512 and B*4501. The high reactivity of IVIg observed with several B* alleles is also comparable to the incidence of HLA-B reactivity of normal non-alloimmunized male sera 11 . IVIg also reacted strongly with a few A* alleles, including A*8001, A*3401, A*4301, A*6601 and A*6602. Interestingly, the high reactivity of IVIg with these A* alleles is strikingly similar to the high incidence of HLA-A reactivity observed with normal male sera 13 .
HLA-Ia alleles on regular beads may occur as intact HLA with β2microglobulin (β2m), as well as heavy chains without β2m, whereas on iBeads, they may occur as intact HLA with much reduced heavy chains. Table 5 shows that the different therapeutic preparations of IVIg differ in their reactivity to intact (regular beads) and heavy-chain HLA (iBeads). Octagam IVIg showed markedly decreased or reduced affinity for iBeads, suggesting its specific affinity for the heavy chain of all HLA-Ia alleles. Following Octagam, one of the lots of Gamunex (NKLK1, from Cedars-Sinai) showed a similar decreased affinity for iBeads whereas the other lot of Gamunex (NKLG1) showed notable increase in MFI with iBeads, strikingly similar to that of Sandoglobulin and Gamastan. All the IVIg preparations showed marked increase in MFI for HLA-A and -B alleles, suggesting that these preparation bind to intact HLA-A and -B alleles.
Decrease in MIF for IVIg preparations for HLA-Cw* alleles suggests that therapeutic IVIg preparations bind to heavy chain of HLA-C alleles. All of the anti-HLA-E mAbs poorly or minimally reacted with iBeads (data not shown), suggesting that the anti-HLA-E mAbs bind mostly to heavy chains of HLA. Anti-albumin antibody reactivity of IVIg.
All four IVIg preparations reacted with the negative control beads coated with albumin ( reactivity of albumin-coated beads also decreased with iBeads, suggesting that the enzymatic treatment given iBeads to remove HLA heavy chain also affects the albumin coated on the beads.
IVIg lost reactivity to both HLA-E and HLA-Ia after HLA-E-Sephadex elution.
To ascertain whether the immunoreactivity to HLA-Ia alleles is due to the anti-HLA-E Abs naturally present in IVIg, the anti-HLA-E Abs were adsorbed out with Sephadex gel conjugated with recombinant HLA-E, then tested for HLA-E and HLA-Ia reactivity. As shown in Figures 6A-B , IVIg immunoreactivity to both HLA-E and HLA-Ia are lost after such adsorbing-out.
Immunization with HLA-E-generated anti-HLA-E mAbs with anti-HLA-Ia reactivity.
In addition to anti-HLA-E Abs, IVIg also contains Abs reacting to HLA-F and HLA-G.
To find out whether anti-HLA-E antibody can also react with HLA-F and HLA-G, and whether such an antibody can still react to HLA-Ia alleles, we generated more than 100 hybridoma clones secreting mAbs that react to HLA-E. Two kinds of mAb groups or clones secreting mAbs are (I) mAbs reacting to HLA-E and HLA-Ia, but not reactive to HLA-F and HLA-G alleles ( Similar to IVIg, both sets of mAbs also reacted less with A* alleles. The HLA-Ia reactivity of these mAbs-as well as IVIg-is comparable with the high incidence of HLA-Ia reactivities found in normal sera 13 .
DISCUSSION
The principal finding, here, is that all pharmaceutical preparations of IVIg tested contain high titers of antibodies to HLA-E and remarkable reactivity to a wide variety of HLA-Ia alleles Alternatively, some other suppressive type of feedback mechanism may be involved to lower HLA antibody production such as that of anti-RhD antibodies 30, 31 . The prevailing mechanism seems to be that the anti-RhD reacts with RhD+ RBC and the complex then inhibits further antibody production 32 . Antigen-specific IgG administered with an antigen can inhibit antigen-specific antibody production 32, 33 . All IVIg preparations show HLA class-Ia antibody reactivity. It is also known that IVIg contains soluble HLA class-I antigens [34] [35] [36] . Possibly, HLA antibodies in IVIg may act similarly to anti-RhD antibodies. Probably, use of a more uniform product-such as the monoclonal anti-HLA-E IgG described in this study (Figure 7 -II)-may yield more consistent results.
One of the primary objectives of using IVIg in patients waiting for transplantation-and for allograft recipients-is specifically to lower the titers of pre-existing and post-transplant anti-HLA Abs 2-5 . This investigation documents that IVIg per se contains reactivity to most of the HLA-Ia alleles (Table 3) . Hence, it is doubtful whether IVIg can lower HLA antibodies, particularly when IVIg by itself contains high HLA-Ia Abs reactivities. Three recent clinical studies document that IVIg preparations were unable to reduce HLA Abs 6-8 . In the first report 6 , IVIg failed to lower the mean percentage of pretransplant HLA Abs observed before IVIg infusion (85% before, 80% after IVIg (p = 0.1). On the contrary, an increase in anti-HLA-Ia Abs was observed after IVIg in 27% of the patients. In the second report 7 , entitled "infusion of highdose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients," the authors confirmed that HLA antibody profiles, measured by calculated-PRA, showed no significant change in response to IVIg treatment. The third report 8 also documented that IVIg-even with Rituximab-did not lead to any significant reduction in patients' anti-HLA-Ia Abs calculated by PRA levels or MFI measured with Luminex single antigen beads. Importantly, none of these studies corroborate previous claims on the reduction of HLA antibodies (calculated panel reactive antibody, CPRA) in sensitized patients undergoing desensitization with high-dose IVIg. These divergent results can be explained by two possibilities: first, that IVIG has no real influence on HLA antibodies as claimed in the reports; second, that due to the extreme variability in the level of HLA antibodies in the different IVIg preparations, as documented here, some IVIg preparations and lots may not have ability to lower HLA antibodies in patients. Indeed, until now, no real evidence has been produced as to exactly what the active ingredient in IVIG is that lowers antibodies.
We were surprised that the HLA antibodies in many of the commercial preparations contained HLA antibodies in high titers, and that these antibodies were often against intact HLA antigens (HLA-A & -B but not Cw). We had assumed that most of the antibodies were against heavy chains of HLA antigens, as reported in normal males 37 . Concentration of these antibodies during the process of purifying IgG might be expected to produce high levels of reactivity against heavy chains of HLA antigens. The antibodies to intact HLA antigens found in IVIg might have come from alloimmunized plasma (e.g., pregnancy plasma), since nonalloimmunized males do not have such antibodies.
The presence of antibodies to intact HLA is of some concern, since in high titers they can be expected to produce TRALI 25 . And indeed, five instances of TRALI following administration of IVIG have been reported [38] [39] [40] [41] [42] , with one death 41 . These studies suggest that further use of IVIg should be preceded by titer tests of HLA antibodies because there is a distinct possibility that the active agent in IVIg is actually the HLA antibody itself. In that case, a careful balancing of the danger of TRALI must be carefully considered, and the effective action of the HLA antibody needs to be monitored when using IVIg. It is likely that TRALI will be produced by antibodies to intact HLA antigens. The other possibility for future use of IVIg is the use of the monoclonal anti-HLA-E antibody-which is against denatured antigens, so unlikely to cause TRALI, and may have the antibody-reducing effect reported for IVIG. Of course, the monoclonal antibody will have the added advantage of being a uniform agent with more predictable effect.
The mechanism of IVIg's action has not been clarified in Increased cellular expression of HLA-E, induced by proinflammatory cytokines (e.g.
IFNγ)
, is correlated with inflammation and malignancy and release of sHLA-E in circulation 45 .
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The sHLA-E occurs without β 2 m. In the intact HLA-E, the presence of β 2 m may mask some of the peptide sequences of the heavy chain. When sHLA-E is devoid of β 2 m, the peptide sequences otherwise masked by β 2 m in intact HLA-E are exposed to elicit immune response. It is estimated that 100 ml of cell-free plasma is sufficient to induce HLA-specific allo-Abs in the recipient 46 . Antibodies to HLA-E may be produced by β2m-free sHLA-E during pathological events such as inflammation. This could be one of the reasons for the presence of anti-HLA-E Abs in alloimmunized males and healthy females. Possibly, the same explanation can be extended for the presence of anti-HLA-E Abs in IVIg. Indeed, immunogenic sHLA class-I molecules were reported in IVIg [34] [35] [36] .
In addition to anti-HLA-E Abs, IVIg may contain anti-HLA-F and anti-HLA-G Abs ( Figures 4A-D) . Observations made of anti-HLA-E mAbs ( Figure 7B ) suggest that the HLA-F and HLA-G reactivities in IVIg could be due to Abs against HLA-E. IVIg also shows reactivity to HLA-Ia (HLA-A, HLA-B and HLA-Cw) ( Figures 5A-C) . Since the anti-HLA-Ia reactivity is lost concomitantly with loss of anti-HLA-E Abs when IVIg is passed through HLA-E-conjugated Affi-Gel, it is inferred that the anti-HLA-E Abs mimic the HLA-Ia reactivity (Figures 6A, B) .
Such a possibility may be realized if the Abs in IVIg recognize an epitope common to HLA-E and HLA-Ia-or even to other HLA-Ib alleles. Table 4 provides the profiles of such shared amino acid sequences or epitopes. These shared epitopes were identified 14[ Table. 1&4] , localized on the heavy-chain polypeptide 15 HLA-B(B) and HLA-Cw(C). If MFI of an HLA allele with iBead is higher (indicated in bold) than that of the regular bead it is indicates that the HLA-reactivity in question is towards intact HLA. Percentage of increase also refers to the same. If MFI of an allele with iBead is lower than that of the regular bead it is indicative of the affinity of the antibody towards heavy chain of HLA. Percentage of decrease also refers to the same. 
The difference in MFI value and percentage of HLA-Ia reactivity of different therapeutic IVIg preparations between Regular beads and iBeads (reduced amount of heavy chain) coated with HLA-A (A),
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Figure Legends
